

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

JC09 Rec'd PCT/PTO 03 JUN 2005

Serial No. : Confirmation No.
Applicant : Banchereau, et al.
Filed : Dec. 4, 2002
TC/A.U. :
Examiner :
Docket No. : BHCS:1028
Customer No. : 34,725

Mail Stop Amendment
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

As listed on the accompanying form PTO-1449, submitted herewith are copies of the indicated references which Applicant believes may be material to the examination of the above-identified application, and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

The filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made, an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists. Further, the filing of this Information Disclosure Statement shall not be construed as an admission against interest in any manner. Written notification that the enclosed references have been considered in their entirety by return of a copy of the enclosed form, completed by the Examiner, is respectfully requested.

**IDENTIFICATION OF TIME OF FILING THE
INFORMATION DISCLOSURE STATEMENT**

- ☐ This Information Disclosure Statement is being filed within three months of the filing date of the national application.
- ☐ This Information Disclosure Statement is being filed within three months of the date of entry of the national stage as set forth in §1.491 in an international application.
- ☒ This Information Disclosure Statement is being filed before the mailing date of the First Office Action on the merits.
- ☐ This Information Disclosure Statement is being filed after three months of the filing date of the national application or after three months of the date of entry of the national stage as set forth in § 1.491 in an international application or after the mailing date of the first Office Action on the merits, but before the mailing date of either a final action under § 1.113 or a notice of allowance under § 1.311, or an action that otherwise closes prosecution in the application.

Accompanying this transmittal is:

- ☐ a statement specified in 37 CFR § 1.97(e); or
- ☐ a fee set forth in 37 CFR § 1.17(p)
- ☐ This Information Disclosure Statement is being filed after the mailing date of a final action under § 1.113, or a notice of allowance under § 1.311 but before the payment of the issue fee.

Accompanying this transmittal is:


1. a statement as specified in 37 CFR § 1.97(e); and
2. a fee set forth in 37 CFR § 1.17(p)

FEE PAYMENT

- ☐ Attached is a check in the amount of \$_____.
- ☐ Charge Deposit Account No. _____ in the amount of \$_____.
- ☒ Applicants believe no additional fees are due for the filing of this IDS.

Respectfully submitted,

CHALKER FLORES, LLP



Edwin S. Flores
Registration No. 38,523
Attorney for Applicant

Dated: June 3, 2005

Chalker Flores, LLP
12700 Park Central
Suite 455
Dallas, Texas 75251
Ph. 214-866-0001
Fax 214-866-0010

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	
				Filing Date	03-29-2001
				First Named Inventor	Banchereau, et al.
				Art Unit	
				Examiner Name	
Sheet	1	of	4	Attorney Docket Number	BHCS:2000

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
		US- 6,004,807	12-21-1999	Banchereau, et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
		WO 02072013	09-19-2002	Banchereau, et al.		

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

JC09 Rec'd PCT/PTO 03 JUN 2005

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	
				Filing Date	
				First Named Inventor	Banchereau, et al.
				Art Unit	
Examiner Name					
Sheet	2	of	4	Attorney Docket Number	BHCS:1028

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		THURNER, et al. Vaccination with MAGE-3A 1 peptide-pulsed mature, monocyte-derived dendritic cells expands scientific cytotoxic T cells and induces regression of some metastases in advance stage IV melanoma. J Exp Med. 1999, Vol. 190, No. 11, Pages 1669-1678.	
		MACKENSEN, et al. Phase 1 study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells. Int J Cancer, 2000, Vol. 86, No. 3, Pages 385-392.	
		NESTLE, et al. Vaccination of melanoma patients with peptide-or tumor lysate pulsed dendritic cells. Nat. Med. 1998, Vol 4. No. 3, Pages 328-332.	
		BANCHEREAU et al. Immune and clinical responses in patients with metastatic melanoma to CD34+ progenitor-derived dendritic cell vaccine. Cancer Res. 2001, Vol. 61, pages 6451-6458.	
		BERARD, et al. Cross-priming of naïve CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogenic melanoma cells. J Exp Med. 2000, Vol. 192 No. 11, Pages 1535-1543.	
		SIENA, et al. Massive ex vivo generation of functional dendritic cells from mobilized CD34+ blood progenitors from anticancer therapy. Exp Hematol, 1995, Vol. 23, No. 14, Pages 1463-1471.	
		ELJAAFARI, et al. Generating of stable monocyte-derived dendritic cells in the presence of high concentration of homologous or autologous serum: influence of extra-cellular pH. Hum Immunol. 1998, Vol. 59, No. 10, Pages 625-634.	
		ALVING, et al. Liposomes as carriers or peptide antigens: induction of antibodies and cytotoxic T lymphocytes to conjugated and unconjugated peptides. Immunol, Rev 1995, Vol. 145, Pages 5-31.	
		HSUEH, et al. Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma call vaccine. J. Clin. Oncol. 1998, Vol. 16, No. 9, pages 2913-2920.	
		HARTUNG, et al. On tests of the overall treatment effect in meta analysis with normally distributed responses, Stat Med 2001, Vol. 20, Pages 1771-1782.A	
		GROSS, et al. Monotoring the immunological status of patients receiving BCG therapy of malignant disease. Cancer, 1976, Vol. 37, No. 5, Pages 2183-2193.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

JC09 Rec'd PCT/PTO 03 JUN 2005

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	
				Filing Date	
				First Named Inventor	
				Art Unit	
				Examiner Name	
Sheet	3	of	4	Attorney Docket Number	
				BHCS:1028	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		RATTA M, et al. Generation and functional characterization of human dendritic cells, derived from CD34 cells mobilized into peripheral blood: comparison with bone marrow CD34+ cells. Br J. Haematol, 1998, Vol. 101 No. 4, Pages 756-765	
		CAO, et al. In vitro generation of dendritic cells from human blood monocytes in experimental conditions compatible for in vivo cell therapy. J Hematother. Stem Cell Res. 2000, Vol. 9, No. 2, Pages 183-194.	
		ARDECHNA, et al. A clinically applicable method for ex vivo generation of antigen-presenting cells from CD34+ progenitors. Vox Sang. 2000, Vol 79, No. 1, Pages 46-52.	
		KNAPP, et al. Improved tests for random effects of meta-regression with a single covariate. Stat. Med. 2003, Vol. 22, Pages 2693-2710.	
		KOWALKOWSKI, et al. Ex vivo generation of dendritic cells from the CD34+ cells in gas-permeable containers under serum-free conditions. J. Hematother. 1998, Vol. 7, No. 5, Pages 403-411.	
		BORRAS, et al. Dendritic cells can be successfully generated from CD34+ cord blood cells in the presence of autologous cord blood plasma. Bone Marrow Transplant. 2000, Vol. 26, No. 4, pages 371-376.	
		SKEA, et al. Adjuvant-independent induction of immune responses by antibody-mediated targeting of protein and peptide antigens. Reg. Immunol. 1992, Vol. 143, No. 5, pages 568-572.	
		CARAYANNIOTIC, et al. Delivery of synthetic peptides by anti-class II MHC monoclonal antibodies induces specific adjuvant-free IgG responses in vivo. Mol. Immunol. 1988, Vol. 25, No. 9, Pages 907-911.	
		BAIU, et al. Modulation of the humoral immune response by antibody-mediated antigen targeting to complement receptors and Fc receptors. J. Immunol, 1999, Vol 162, pages 3125-3130.	
		SCHJETNE, et al. Cutting edge: Ling between innate and adaptive immunity: Toll-like receptor 2 internalizes antigen for presentation to CD4+ T cells and could be an efficient vaccine target. J Immunol. 2003, Vol. 171, Pages 32-36.	
		CHAKRABORTY, et al. Immunization with a tumor-cell-lysate-loaded autologous-antigen-presenting-cell-based vaccine in melanoma. Cancer Immunol. Immunother. 1998, Vol. 47, Pages 58-64.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	
				Filing Date	
				First Named Inventor	Banchereau, et al.
				Art Unit	
				Examiner Name	
Sheet	4	of	4	Attorney Docket Number	BHCS:1028

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		PALUCKA, et al. Blood dendritic cells: Multi-potential differentiation or committed subsets? Blood. 15 November 1999, Vol. 94, No 10, Page 48.	
		GLUCKMAN, et al. In vitro generation of human dendritic cells and cell therapy. Cytokines, Cellular and Molecular Therapy. 1997, Vol. 3, pages 187-196.	
		CHOI, et al. Analysis of Methods for the Generation of Dendritic Cells from Human Peripheral Blood Monocytes. Yonsei Med. J. 2000, Vol. 41, No. 5, pages 642-650.	
		FEUERSTEIN, et al. A method for the production of cryopreserved aliquots of antigen-preloaded, mature dendritic cells ready for clinical use. J. Immunol. Methods. 2000, Vol. 245, pages 15-29.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.